


Redx Pharma Plc

- Redx AI division established April 2013 at Alderley Park
- Sixty research scientists (microbiologists, DMPK, computational and medicinal chemistry)
- Focus on overcoming existing anti-microbial resistance mechanisms:
 - Gram +ve program: Development candidate selected
 - Gram –ve program: Lead optimisation
- Work collaboratively with academics, the NHS, BEAM alliance, large pharma and ENABLE
- Open to partnerships; Happy to discuss at BIO
- M.craighead@redxpharma.com
- www.redxpharma.com

Gram negative program overview

- Three series of novel, non-quinolone, inhibitors of the bacterial type II topoisomerases, DNA gyrase and topoisomerase IV
- Potent compounds with broad/ narrow spectrum of activity against resistant strains including recent clinical isolates
- Low frequency of resistance with balanced activity at both target enzymes
- PK properties suitable for iv dosing

	LVX	REDX07027	REDX07208	REDX07609
<i>A. baumannii</i>	16	2	0.5	4
<i>P. aeruginosa</i>	64	4	2	8
<i>E. cloacae</i>	32	16	4	16
<i>E. coli</i>	16	2	1	4
<i>K. pneumoniae</i>	16	16	4	16



Gram positive program overview

- Development candidate selected
- Inhibit bacterial DNA Gyrase without chelating Mg^{2+} - by-pass resistance observed with FQ antibiotics
- X-ray studies confirm differential binding from quinolones
- Broad spectrum of activity including resistant strains (*S. aureus*, *S. epidermidis* & *S. pyogenes*)
- Excellent activity in mouse thigh, septicaemia & *N. gonorrhoeae* models

